Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DAVID who wrote (21643)	5/5/1999 2:55:00 PM
From: Linda Kaplan	Read Replies (1) \| Respond to of 23519

Yup. That's what the lawyer at one of the firms who was suing VVUS told me. Do nothing. Wait for forms in mail. Sign and mail forms. --Linda

To: DAVID who wrote (21643)	5/5/1999 3:06:00 PM
From: DaiS	Read Replies (1) \| Respond to of 23519

Today's press release is already on the Vivus web site...usually it takes days. I think that the viagra failure abstract is the first time that Vivus have referred to viagra on their site. IMO Past Vivus strategy has been not to concede that muse is anything other than an equal competitor to viagra re effectivness and that it is superior re safety. Then to attribute the drop in muse sales to vast viagra hype. Implicit in the current abstract is that men would prefer viagra, then if fail try muse. Tricky to release without admitting that muse second best, easier to press release a combo study IMO. Perhaps Leland referring to web site is a compromise. We have to note what Zebra says that Vivus unwise to hype the gene therapy abstracts until concrete event such as initiation of trials or patent etc. Maybe safety abstract better to release when next viagra death count release Guess I'm just trying to rationalize why no press release from AUA or Astra